Cadila Healthcare Limited

Rajesh Bahekar

Mukul R Jain

Pankaj Ramanbhai Patel

Ranjit C Desai

Rajendra Chopade

Gaurav Gupta

Braj Bhushan Lohray

Vidya Bhushan Lohray

Suresh Giri

Kaushik M Banerjee

Vijay Prajapati

Dipam Patel

Kiran Shah

The present invention relates to novel short chain peptides of formula (I) which can be useful as a vaccine when in conjugation with suitable immunogenic carrier and suitable adjuvant. These are useful for the treatment for the PCSK9 mediated diseases.A-Z-Z-Z-Z-Z-Z-Z-Z-Z-Z-Z-Z-B&#x2003;&#x2003; Formula (I)

Peptide based PCSK9 vaccine

The present invention relates to novel short-chain peptides of the general formula (I), which are selective and peripherally acting KOR agonist, their tautomeric forms, their enantiomers, their diastereoisomers, their stereoisomers, their pharmaceutically accepted salts, or prodrugs thereof which are useful in the treatment or prevention of diseases in which the Kappa (&#x3ba;) opioid receptors (KOR) are involved, such as treatment or prevention of visceral pain, hyperalgesia, rheumatoid arthritic inflammation, osteoarthritic inflammation, IBD inflammation, IBS inflammation, ocular inflammation, otitic inflammation or autoimmune inflammation. The invention also relates to process for the manufacture of said short-chain peptides, and pharmaceutical compositions containing them and their use.

Short-chain peptides as Kappa (&#x3ba;) opioid receptors (KOR) agonist

The present invention relates to heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as selective Bruton's Tyrosine Kinase (BTK) inhibitors. 

Heterocyclic compounds

The present invention provides novel peptidomimetics, of formula (I), which primarily act as glucose dependent insulin secretagogues. Furthermore, it was found that these peptidomimetics showed glucagon receptor antagonistic activity, along with the GLP-I receptor agonistic activity.

Peptidomimetics with glucagon antagonistic and GLP 1 agonistic activities

The present invention provides novel peptidomimetics, of formula (I), which primarily act as glucose dependent insulin secretagogues. Furthermore, it was found that these peptidomimetics showed glucagon receptor antagonistic activity, along with the GLP-1 receptor agonistic activity.A-Z&#x2014;Z&#x2014;Z&#x2014;Z&#x2014;Z&#x2014;Z&#x2014;Z&#x2014;Z&#x2014;Z&#x2014;Z&#x2014;Z&#x2014;B&#x2003;&#x2003;(I)

Antidiabetic compounds

The present invention provides novel short-chain peptides, which primarily act as parathyroid hormone (PTH/PTH-1) receptor agonist. These short-chain peptides exhibit increased stability to proteolytic cleavage. Most of short-chain peptides were found to be stable in rat plasma up to 24 hours (in vitro), showed increased stability against GIT enzymes such as pepsin and acidic stomach pH and also against liver microsomes (in vitro). Due to increased metabolic stability, other than parenteral route of administration, some of the short-chain peptides can also be delivered by oral routes of administration, for the treatment/prevention of hypoparathyroidism and diseases characterized by bone mass reduction, such as osteoporosis, postmenopausal osteoporosis and for stimulating bone repair.A-Z-Z-Z-Z-Z-Z-Z-Z-Z-Z-Z-Z-Z-Z-Z-B

Growing community of inventors

Gujarat, India

Rajesh Bahekar